Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Intranasal Insulin on Postoperative Cognitive Dysfunction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04154449
Recruitment Status : Recruiting
First Posted : November 6, 2019
Last Update Posted : November 6, 2019
Sponsor:
Information provided by (Responsible Party):
Nourhan mohamed anter, Minia University

Brief Summary:

Our study is designed to evaluate the effect of intranasal insulin on postoperative cognitive dysfunction.

Primary outcome:

1. The occurrence of cognitive dysfunction at approximately 7 days after surgery.

Secondary outcome:

1. Incidence of any side effect.


Condition or disease Intervention/treatment
Middle Aged Patients Drug: Intranasal insulin

Layout table for study information
Study Type : Observational
Estimated Enrollment : 57 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Effect of Intranasal Insulin on Postoperative Cognitive Dysfunction in Middle Aged Patients Undergoing Non Cadiac Surgery.
Actual Study Start Date : February 25, 2019
Estimated Primary Completion Date : December 25, 2019
Estimated Study Completion Date : December 25, 2019

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Control group.
Surgical group Received intranasal insulin. Drug: Intranasal insulin
Surgical group Received intranasal insulin, the second group surgical Received placebo and the third group is non surgical do not receive anything.

Surgical group Received placebo.



Primary Outcome Measures :
  1. Cognitive dysfunction [ Time Frame: 7 days ]
    The occurrence of cognitive dysfunction at approximately 7 days after surgery.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
  1. Age 40 - 60 years.
  2. Both gender.
  3. Patients will be scheduled for elective major abdominal, thoracic, orthopedic, open gynecological, open urological, spine, otolaryngological surgeries under general anesthesia with expected hospital stay >4 days.
Criteria

Inclusion Criteria:

  1. Age 40 - 60 years.
  2. Both gender.
  3. Patients will be scheduled for elective major abdominal, thoracic, orthopedic, open gynecological, open urological, spine, otolaryngological surgeries under general anesthesia with expected hospital stay >4 days.

Exclusion Criteria:

  • 1. Drug allergy. 2. Patients with major psychiatric disease. 3. Patients receive major tranquillizers and antidepressant. 4. Those undergoing neurosurgery or cardiac surgery. 5. Those unable or unwilling to abide by the study procedure 6. Those who could not follow procedure or who had poor comprehension of dutch language. 7. Those with sever visual and auditory disorder / handicaps.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04154449


Contacts
Layout table for location contacts
Contact: Nourhan Mohamed Anter 01100418846 ext 01012660236 nourhananter1992@yahoo.com

Locations
Layout table for location information
Egypt
Minia University Recruiting
Minya, Egypt, 61111
Contact: Nourhan NM Mohamed Anter, Resident    01100418846    nourhananter1992@yahoo.com   
Minia university Completed
Minya, Egypt, 61111
Sponsors and Collaborators
Minia University
Layout table for additonal information
Responsible Party: Nourhan mohamed anter, Resident of anesthesia and Intensive care, Minia University
ClinicalTrials.gov Identifier: NCT04154449    
Other Study ID Numbers: 164: 2/2019
First Posted: November 6, 2019    Key Record Dates
Last Update Posted: November 6, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cognitive Dysfunction
Cognition Disorders
Neurocognitive Disorders
Mental Disorders
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs